What reimbursement for coronary revascularization with drug-eluting stents?
We investigated the clinical and economic impact of sirolimus-eluting coronary stents (SES) at a nationwide level as to advice about the feasible reimbursement policy for the Italian Health Care System (SSN). A decision model compared bare metal stents (BMS) and SES in terms of costs and repeat coronary revascularizations incurred in 12 months following the first revascularization. The model was compiled for eight subgroups of patients. Rates of events were derived from randomized trials and an 1,809-patient survey. National charges were used to evaluate resources consumption. Compared with BMS, the number of averted revascularizations with SES is 0.16 per patient. SES also save Euro 1,371 per patient. Total savings to SSN are proportional to the rate of SES adoption by Italian hospitals: assuming a complete replacement of BMS with SES, the model estimates that 7,095 revascularizations would be averted and more than Euro 60 million saved by the SSN in 1 year. To stimulate SES adoption a SES-specific DRG might by introduced with a reimbursement value 23% higher than the current charge. SES is thus a cost-saving strategy in the perspective of the SSN that could therefore support the introduction of the new technology by reimbursing about 80% of its current incremental acquisition cost.
Tarricone
Rosanna
R
CeRGAS-SDA Bocconi University, Milan, Italy. rosanna.tarricone@uni-bocconi.it
Marchetti
Monia
M
Lamotte
Mark
M
Annemans
Lieven
L
de Jong
Peter
P
D023903:Coronary Restenosis / Q000191:economics / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D005260:Female; D017721:Hospital Costs; D006801:Humans; D007558:Italy; D008297:Male; D018803:Models, Economic; D009204:Myocardial Revascularization / Q000191:economics; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D020123:Sirolimus / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D015607:Stents / Q000191:economics*; D016896:Treatment Outcome
D010975:Platelet Aggregation Inhibitors; D020123:Sirolimus